10.4 C
New York
Friday, April 19, 2024

Patents Granted For 22nd Century Group’s Technology To Virtually Eliminate Nicotine In Tobacco Plants

Courtesy of Benzinga.

22nd Century Group, Inc. (NYSE MKT: XXII) today announced that the U.S. Patent and Trademark Office (USPTO) on July 29, 2014 and the Korean Intellectual Property Office on July 23, 2014, each granted a patent to the Company for its NBB technology that virtually eliminates nicotine in the tobacco plant. The resulting tobacco plants are planted, grown, harvested, cured, processed, and made into tobacco products, including cigarettes, exactly the same as conventional tobacco.

U.S. Patent 8,791,329, Reducing Levels of Nicotinic Alkaloids in Plants, contains 33 claims. South Korean Patent 10-1413122, also titled, Reducing Levels of Nicotinic Alkaloids in Plants, contains 15 claims. These two patents and related International Patent Application PCT/IB2006/001741, cover methods for producing tobacco plants with decreased nicotine levels and the resulting tobacco plants and products produced therefrom. There are various continuation and divisional patent applications related to these granted patents pending in both patent offices.

The term of U.S. Patent 8,791,329 has been extended by the USPTO by 1,309 days due to prosecution delays at the USPTO. Joseph Pandolfino, 22nd Century Group’s Founder and CEO, stated, “We are pleased that the USPTO’s patent term adjustment will extend the life of this key Company patent through September 2029. This technology will be utilized worldwide for our next generation very low nicotine (VLN) cigarettes, which we expect to have approximately 1% of the nicotine of conventional cigarettes – a 99% reduction.” Conventional tobacco can easily be blended with the Company’s VLN tobacco to produce tobacco with any desired nicotine content.

Patent applications for the NBB technology have been filed by 22nd Century worldwide and patents are currently issued to 22nd Century in the U.S., China, Europe, Japan, South Korea, Taiwan, Mexico, Australia and South Africa.

The NBB gene encodes a protein, “nicotine synthase,” that is involved in the final step of nicotine biosynthesis. Having eluded scientists for decades, this protein can be down-regulated or up-regulated to produce tobacco varieties with a wide range of nicotine levels.

Posted-In: News Legal Press Releases

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,350FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x